Connect with us

Featured Stocks

Planet 13 Stock (CNSX:PLTH) (OTCMKTS:PLNHF): Is It A Buy Or Sell?

Published

on

Planet 13 stock

The marijuana stocks universe presents a variety of choices. But not all choices are great. You want to put your money in a marijuana company with a strong competitive advantage, great growth potential, and solid financials. If you are looking for a great pot stock to buy heading into 2020, Planet 13 stock (CNSX:PLTH) (OTCMKTS:PLNHF) is a strong candidate.

About Planet 13 stock

For investors who may be learning about Planet 13 Holdings for the first time, this is a vertically-integrated marijuana business. It is one of the leading marijuana companies in the Nevada market. Planet 13 Holdings is engaged in the cultivation, processing, and retail of marijuana products and it already has several marijuana brands to its credit. It operates the largest marijuana retail outlet in the world.

What you should know about Planet 13 stock

For marijuana sector in general, 2019 has generally been a rough year. Many marijuana stocks have dropped to multiyear lows. As the charts show, Planet 13 Holdings stock has been through a lot of ups and downs this year. Still, those swings have delivered decent returns for investors who know how to play stocks like Planet 13 Holdings in volatile periods.

Presently, Planet 13 Holdings stock is trading at $1.64. The stock began the year at $1.00. It jumped to $1.64 in February, thereby returning nearly 65% in space of a few weeks. There was a period of profit-taking following the January surge, resulting in the stock coming down to $1.25. From there, it began moving up again, reaching its 2019 peak of $2.62 in April and delivering a return of 110% to investors who picked up the stock at its previous low.

Why Planet 13 stock is poised for greater highs

Stock up and down moves typically create short-term profit opportunities for investors who can play a volatile stock market to their advantage. But Planet 13 Holdings is more than a short-term profit stock. Here are three reasons you may want to add Planet 13 Holdings stock to your portfolio going into 2020.

  • No other company except Planet 13 Holdings owns and operates the world’s largest marijuana retail outlet

In November 2018, Planet 13 Holdings opened SuperStore, a marijuana retail complex just west of Las Vegas strip, Nevada. Planet 13’s SuperStore is a 112,000 square feet facility that also hosts a restaurant in addition to marijuana shop and on-site marijuana processing unit.

Sales have been booming at the SuperStore. Through the facility alone Planet 13 fills about 10% of all marijuana sales in the entire state of Nevada. Through its SuperStore facility, Planet 13 Holdings has positioned itself well to take full advantage of the growing demand for marijuana products in Nevada. Nevada’s marijuana market, comprising sales of medical and recreational marijuana products, generated $580 million in revenue in 2018, ArcView Market Research and BDS Analytics estimates show. The market will grow to $795 million by 2022.

Having seen the early success of SuperStore, Planet 13 plans to open another world-class marijuana retail complex. It plans to open what would be the world’s second-largest marijuana retail outlet in Santa Ana, California, next year. The Santa Ana complex will sit just a few miles from busy sites such as the South Coast Plaza Mall and Disneyland. California has one of the fastest-growing marijuana markets. California’s marijuana sales hit $2.5 billion in 2018 and will jump to $5.6 billion by 2022.

  • Planet 13 Holdings is well-capitalized to pursue its development dreams

Presently, credit funding opportunities are limited for marijuana companies in the United States. That is because big banks have generally shunned doing business with marijuana companies for fear of running afoul of federal regulations.

Congress is working on a solution to this challenge. However, Planet 13 Holdings isn’t waiting for Congress to pass laws that would make obtaining loans from big banks easy before it can develop its business and create value for shareholders. Planet 13 is one of the few well-capitalized marijuana companies. The company disclosed in its third-quarter report that its current capital position allows it to complete all its growth initiatives.

  • Planet 13 Holdings is a marijuana company that investors can trust

Investors may not have any doubts regarding financial services or technology stocks because these are well-established industries with clear regulations. But marijuana is different. The industry is new and regulation is far from complete, especially considering that marijuana remains federally illegal in the United States.

Planet 13 Holdings is doing a great job to overcome doubts that investors may have about its business. Every few weeks, Planet 13 issues a press release to update investors on its operations. This past November, for instance, Planet 13 issued five press releases. That ensures that investors stay up-to-date with the directions the company is taking and can make informed investment decisions. To win over more investors, building trust is important and Planet 13 does just that.

Bottom line

Planet 13 stock stands out in the marijuana universe as a stock that can deliver excellent returns. Now trading close to its multiyear lows, Planet 13 stock looks primed for a big breakout.

We will be updating our subscribers as soon as we know more. For the latest updates on Planet 13 stock, sign up below!

Disclosure: We have no position in Planet 13 stock and have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured Stocks

Why Lexaria Bioscience Corp (OTCMKTS:LXRP) Is A Comeback Play

Published

on

Lexaria Bioscience

Lexaria Bioscience Corp (OTCMKTS:LXRP) brightest days lie ahead. The sentiments shared by Chief Executive Officer, Chris Bunka, are slowly coming to fruition, going by recent price action activity. After a steep pullback in 2019, the stock has once again started climbing higher, as investors react to milestones achieved in 2019 that affirm long-term prospects.

Lexaria Bioscience Catalysts and Price Analysis

A confirmation that the global innovator in drug delivery systems achieved almost everything it set out to accomplish in 2019 continues to strengthen market sentiments. The inking of strategic partnerships with Fortune 500 style companies is another development that the management continues to tout.

Likewise, Lexaria Bioscience succeeded in getting its DehydraTECH technology to market, consequently creating an avenue for generating long-term value. The company’s Intellectual Property strategy has also started to pay dividends, affirming what is at stake going forward. Reports that the company is already experiencing an increase in revenues is another catalyst that continues to shore the stock’s sentiments and prospects in the markets.

Lexaria Bioscience has already started bottoming out from all-time lows in what appears to be the development of a positive trend. A 10% plus rally from one-year lows continue to fuel optimism that the stock has clocked a bottom and due for a correction higher.

Standing in the way of the emerging uptrend is the $0.50 mark, which is the immediate short-term resistance level. A rally followed by a close above the…

Continue Reading

Featured Stocks

Helix TCS Stock (OTCMKTS:HLIX): A Fundamentally Attractive Investment

Published

on

Helix TCS stock

Helix TCS Stock (OTCMKTS:HLIX) is turning out to be an interesting pick after a steep pullback in 2019. The stock appears to be trading at a big discount going by the solid fundamentals that support a bounce back from current lows. If you are looking for a company seeing plenty of opportunities on the horizon then Helix TCS stock fits the bill.

Helix TCS Stock Catalysts and Price Analysis

The company is currently ranked at number 32 on the Deloitte Technology 500 fastest growing companies. The impressive rating stems from the company reporting impressive financial results depicted by an 80% increase in revenue and a 39% increase in cash flow from operations.

Likewise, the company has moved to strengthen its prospects in the hemp business by launching the nation’s first hemp tracking system. Similarly, the company has inked a strategic partnership with Alt Thirty Six for the launch of digital payments targeting thousands of dispensaries across the U.S

Reports that Helix TCS BioTrack traceability stem processed over $11 million transactions in the first week of recreational sales attest to what could turn out to be a break out year for the company and its technology.

It thus does not come as a surprise that the company’s stock has started to pick up some steam after a roller coaster 2019. A 10% plus rally since the start of the year affirms renewed investor interest in response to the wave of…

Continue Reading

Featured Stocks

Why OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Is A Promising Stock In 2020

Published

on

OWC Pharmaceutical Research

In 2020, investors are looking for cannabis stocks that can deliver excellent returns following a disappointing 2019, which saw many pot stocks crash to multiyear lows. OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) stands out as a promising cannabis stock to own in 2020.

About OWC Pharmaceutical Research

The cannabis stock universe is vast, so for investors who may have just come across OWC Pharmaceutical for the first time an introduction of the company is in order.

OWC Pharmaceutical is an Israel-based cannabis research company. It is focused on research and development of cannabis-based medical products. The company’s work currently includes development of cannabis-based treatments for a variety of diseases and disorders such as multiple myeloma, psoriasis and fibromyalgia.

Moreover, OWC Pharmaceutical provides consulting services to both government and private entities in the field of medical cannabis programs.

OWC Pharmaceutical Research exited 2019 on a high note

While 2019 ended up being one of the toughest year for cannabis stocks, OWC Pharmaceutical had strong finish to the year. The stock gained 35% on December 31. Before that, the stock rose 65% on December 30. The back-to-back gains in the final days of 2019 helped OWC Pharmaceutical cut its losses for the year but also signaled improving investor sentiment on the stock heading into the new year.

OWC Pharmaceutical finished 2019 at $0.089, having pulled from a low of $0.0045 at the beginning of December.

What…

Continue Reading

MJ Stocks